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Obsessive-compulsive disorder (OCD) is a mental disorder characterized by obsession, in which intrusive thoughts or images 
that cause anxiety and stress are repeated, and by compulsion, in which behaviors aimed at reducing such anxiety are repeated. 
In this paper, drug treatment for OCD is described based on randomized controlled trials (RCTs) and open-label trials listed 
in PubMed (www.pubmed.gov; US National Library of Medicine, National Institutes of Health). In addition, we will summarize recent 
challenges in the treatment of obsessive-compulsive disorder.
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INTRODUCTION
Obsessive-compulsive disorder (OCD) is a mental dis-
order characterized by obsession, in which intrusive 
thoughts or images that cause anxiety and stress are re-
peated, and by compulsion, in which behaviors aimed at 
reducing such anxiety are repeated.1) The average lifetime 
prevalence of OCD is 3.0% [average age of onset: 19 
years (14-30 years)].2-4) Two-thirds of OCD patients suffer 
from comorbid mental disorders5) that impose a heavy 
burden on their family members.6) Treatment methods for 
OCD can be categorized into biological and non-bio-
logical methods. Among the many treatment methods, on-
ly the efficacy of drug treatment and cognitive behavior 
therapy has been sufficiently proven. In this paper, OCD 
drug treatment is described based on randomized con-
trolled trials (RCTs) and open-label trials listed in 
PubMed (www.pubmed.gov; US National Library of 
Medicine, National Institutes of Health).
SEROTONIN REUPTAKE INHIBITORS
OCD drug treatment was initiated in the late 1960s after 
clomipramine (CMI), a type of tricyclic antidepressant 
(TCA) and a 3-chlorinated analog of imipramine, was 
found to alleviate compulsive symptoms. Since then, the 
superiority of CMI over other drugs in the treatment of 
compulsive symptoms has been shown in many dou-
ble-blind clinical trials,7-13) which prompted the Food and 
Drug Administration (FDA) to approve it as the first an 
anti-OCD drug. CMI is not currently used as a first-line 
OCD treatment because it may cause various adverse re-
actions, similar to other tricyclic antidepressants, includ-
ing anticholinergic side effects, sedation and sleepiness 
due to its antihistamine effects, and, in particular, postural 
hypotension and conduction defect due to the inhibition of 
the α-adrenaline receptor, which may result in serious 
side effects, such as congestive heart failure or sudden 
death.14) Based on the clinical and pharmacological prop-
erties of CMI, which suppresses serotonin, the “serotonin 
hypothesis” was established, and studies conducted based 
on this hypothesis showed that selective serotonin reup-
take inhibitors (SSRIs) were comparable to CMI in terms 
of their efficacy as a treatment for OCD.7-11,15) SSRI ad-
ministration is now recommended as the first-line treat-
ment for OCD.16) Six types of SSRIs have been introduced 
for clinical use. Four SSRIs have been shown to be effec-
tive in the treatment of OCD by meta-analyses and in more 
than ten RCTs. These four types of SSRIs have been ap-
proved by the FDA for the treatment of OCD, and are as 
follows: 1) fluoxetine;8-10,17,18) 2) fluvoxamine;7-11) 3) pa-
roxetine;18-20) and 4) sertraline.8-10,17,21) Citalopram, which 
has been used in Europe,22,23) and escitalopram, which is 
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Table 1. Recommended SRIs in treatment of OCD patient
KAT-OCD
recommend-
ed mean
dose (mg)
TAK-OCD
recommend-
ed maximum
dose (mg)
ECG-OCD
recommend-
ed dose
(mg)
ECG-OCD
recommend-
ed maximum
dose (mg)
Fluoxetine  50  80  50  80
Sertraline 200 250 150 225
Paroxetine  60  80  50  60
Citalopram  50  80  -  -
Fluvoxamine 200 300 200 300
Clomipramine 180 260 200 300
OCD, obsessive compulsive disorder; TAK-OCD, treatment algo-
rithm for Korean OCD patient; ECG-OCD, expert consensus 
guidelines for OCD patient.
composed of only the active S-isomer of citalopram,24-27) 
have been shown to be effective in the treatment of OCD 
in many open-label studies and RCTs, although they have 
not been approved by the FDA. In particular, citalopram is 
available in an intravenous formulation and is effective in 
the treatment of OCD.28)
INITIAL DRUG TREATMENT OF OCD
In the initial drug treatment of OCD, it is important to 
treat OCD with proper SSRI administration at an adequate 
dose for a sufficient period of time. In addition, first-line 
treatment type, proper dose, and sufficient administration 
period should be decided prior to the next treatment phase. 
In this context, the following recommendation (Table 1) 
was made in the Treatment Algorithm for Korean OCD 
Patients 2007 (II), which was developed in a study or-
ganized by the Korean College of Neuropsychopharma-
cology. The administration of fluoxetine, sertraline, pa-
roxetine, or citalopram (escitalopram) was recommended 
by experts as the first-line treatment, as no particular sero-
tonin reuptake inhibitor (SRI) was more effective.14,16) 
The average SSRI recommended doses for OCD treat-
ment are 50 mg fluoxetine, 200 mg sertraline, 60 mg pa-
roxetine, 50 mg citalopram, 200 mg fluvoxamine, and 180 
mg clomipramine. In a significant number of patients, 
higher doses of SSRIs were more effective than lower 
doses in the treatment of OCD. For example, 20 and 40 mg 
fluoxetine were more effective than placebo, but 60 mg 
fluoxetine was most effective.29,30) In a double-blind trial 
(low-dose group: sertraline 200 mg; high-dose group: ser-
traline 200-450 mg) for OCD patients who did not respond 
to acute treatment, the high-dose group showed better 
treatment effects than the low-dose group.34) In addition, a 
recent open-label trial on escitalopram showed that the de-
gree of compulsive symptom alleviation was greater in the 
high-dose group than in the low-dose group24) and that a 
high dose of escitalopram was effective in patients with 
severe OCD.28) A high SSRI dose is more likely to cause 
adverse reactions than a low dose, and the use of SSRI in 
children, adolescents, and young adult patients with con-
current mental disorders is likely to increase the risk of 
suicide for the first month of administration. As such, care 
must be taken in the use of such medication.31)
TREATMENT STRATEGY FOR  
TREATMENT-RESISTANT PATIENTS
Evaluation of the Treatment Response
The Yale-Brown Obsessive-Compulsive Scale (Y- 
BOCS), which was designed to enable the comprehensive 
measurement of the severity of obsessive thoughts and 
compulsive behaviors, is the most widely used evaluation 
tool in the study of OCD.32) It consists of ten items, each 
rated from 0 to 4 (total score of 32-40, extreme; 24-31, se-
vere; 16-23, moderate; 8-15, subclinical).14) In general, 
treatment response is defined as a 25% or greater reduc-
tion in the Y-BOCS score. Remission is defined as a 
Y-BOCS score of 8 or lower, where the patient can per-
form normal daily functions with slight or no depression 
and is no longer considered to meet the diagnostic criteria 
for OCD.33)
Dose Increase or Replacement of the Initial Medication
For the initial medication for the treatment of OCD pa-
tients, one SSRI-type drug should be chosen and ad-
ministered at a proper dose for a sufficient period. 
Clinicians must decide which treatment strategy to use for 
the next phase, as over 40% of OCD patients do not re-
spond to the initial standard medication.
The Treatment Algorithm for Korean OCD Patients, 
which was developed by experts,16) recommends that if 
patients do not respond to the average SSRI dose in the ini-
tial treatment, the dose should be increased to the max-
imum level recommended if an adverse reaction does not 
occur (Fig. 1). SSRIs are known to be safe even when ad-
ministered at high doses, and several open-label24,25) and 
controlled studies34) have shown that high-dose SSRI is 
effective for treatment purposes. If no improvement is 
seen in the symptoms even after the appropriate SSRI 
treatment, changing the medication to another SSRI is rec-
ommended (Fig. 1). If partial improvement is seen, a com-
bination medication with other drugs is recommended. In 
some cases, to determine the most appropriate drugs for 
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Fig. 1. Treatment algorithm for Korean 
OCD patient. CBT, cognitive be-
havioral therapy; SSRI, selective se-
rotonin reuptake inhibitor; BDZ, ben-
zodiazepine; Li, lithium; SSRI, sero-
tonin reuptake inhibitor; ECT, elec-
tro convulsive therapy; TMS, trans-
cranial magnetic stimulation; DBS, 
deep brain stimulation.
the treatment of certain patients, more than two types of 
SSRIs are used. When a single administration of more 
than two types of SSRIs fails, CMI is recommended.14) 
CMI is less effective and less tolerated than SSRIs be-
cause of the higher occurrence of adverse reactions when 
it is administered. Therefore, the administration of CMI is 
not appropriate as the first-line treatment unless the pa-
tient’s history shows that the administration of CMI was 
previously effective for him or her.14,16)
Combination Medication or Consolidation Therapy
For treatment-resistant cases where SSRI mono-ther-
apy consisting of more than two types of SSRIs fails, the 
Treatment Algorithm for Korean OCD Patients recom-
mends the following: 1) the addition of other drugs, 2) the 
addition of or a change to CMI, or 3) the addition of anti-
psychotic drugs (Fig. 1).
Addition of Drugs that Influence the Effects of SSRIs 
and Serotonin
The differential effects of SSRI on OCD were shown in 
double-blind clinical trials, and the serotonin hypothesis 
was proposed based on these results. Combination medi-
cation is based on the theory of serotonin neurotrans-
mission enhancement, in which substances that enhance 
serotonin transmission are added to SSRI. Although the 
effects of these drugs have been studied by many re-
searchers, their clinical use is rare due to patients’ adverse 
reactions.
Addition of Norepinephrine Reuptake Inhibitors
Some researchers suggested that CMI is effective for 
the treatment of OCD because it inhibits both serotonin 
and norepinephrine reuptake. According to this idea, the 
combination medication of SSRI and norepinephrine re-
uptake inhibitors can be expected to result in an effect sim-
ilar to that of CMI. In one study, however, desipramine, a 
selective norepinephrine reuptake inhibitor, was added for 
patients who did not respond to a single administration of 
SSRI without positive results.35)
Addition of Drugs that Influence the Effects of Dopamine 
and/or Serotonin
The Treatment Algorithm for Korean OCD Patients 
recommends that antipsychotic drugs be added for pa-
tients who do not sufficiently respond after two types of 
SSRIs have been attempted.16) It is recommended that pri-
ority be given to risperidone, olanzapine, and quetiapine 
(in that order) in the choice of drug to add.
Typical antipsychotic drugs
Most of the results of the early studies on single-medi-
cation OCD treatments were negative, but a few were pos-
itive, mostly in patients with schizophrenia.36) Following 
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Table 2. Recommended agumenting AAPs in treatment re-
fractory OCD patient (TAK-OCD)
Recommended
mean
dose (mg)
Recommended
minimum
dose (mg)
Recommended
maximum
dose (mg)
Risperidone   3.4   2   4
Olanzapine   9.6   5  15
Quetiapine 271.5  50 300
Zpirasidone  69  40  80
Amisulpride 316.7 200 400
Aripiprazole  14.2  10  20
Haloperidol   6   5  15
TAK-OCD, treatment algorithm for Korean OCD patient.
these studies, positive results were obtained in an open-la-
bel trial in which fluvoxamine and pimozide were used37) 
and in a double-blind placebo-controlled study in which 
fluvoxamine and haloperidol were used.38) Most of the pa-
tients who showed a remarkable decrease in symptoms af-
ter the addition of antipsychotic drugs to their medication, 
however, had a concurrent tic disorder.
Atypical antipsychotic drugs
Clinicians have begun to pay attention to atypical anti-
psychotic drugs because of typical antipsychotic drugs’ 
limited effectiveness and low tolerance. After the treat-
ment effects of atypical psychotic drugs were shown in 
some studies where adjunctive risperidone with SSRI was 
used,39-42) risperidone and many other atypical anti-
psychotic drugs have been used as an adjunctive drug to 
SSRIs. The Treatment Algorithm for Korean OCD Pa-
tients showed that treatment-resistant OCD patients bene-
fitted from augmentation with atypical antipsychotics 
(AAPs; Table 2). The use of AAPs, however, as an ad-
junctive drug to SSRIs for patients with SSRI resistance 
resulted in a treatment effects in only some patient groups, 
indicating that the use of AAPs may be limited consider-
ing the drugs’ safety issues.43)
Risperidone
Four early open-label trials showed that adjunctive ris-
peridone was effective for the treatment of OCD patients 
who were resistant to single SSRI administration.39-42) 
This was confirmed in double-blind placebo-controlled 
studies; a 40-50% response in the risperidone-admini-
stered groups and a less than 20% response in the place-
bo-administered groups clearly demonstrated the effect of 
adjunctive risperidone.
Olanzapine
Six open-label trials showed very encouraging re-
sults,44-49) and a placebo-controlled study supported the ef-
fectiveness of olanzapine.50) However, a double-blind pla-
cebo-controlled study conducted by Shapira et al.51) did 
not support olanzapine’s effectiveness. A study conducted 
by Marazziti et al.52) suggested that olanzapine could be 
effective as an adjunctive drug. Another study that com-
pared the effectiveness of adjunctive risperidone and olan-
zapine also showed no difference in the effectiveness of 
the two adjunctive drugs. Therefore, positive results from 
further studies are expected.
Quetapine
The effectiveness of quetiapine has been shown in 
many open-label trials53,54) and small-scale controlled 
studies,55) but not in subsequent larger controlled stu-
dies.56,57) Recently, positive results were obtained from a 
study conducted to compare the effectiveness of placebo 
and quetiapine for the treatment of patients with treat-
ment-resistant OCD.58) In another study conducted to 
compare the effectiveness of CMI and quetiapine as ad-
junctive drugs, only the quetiapine-administered groups 
showed significant effects. The use of adjunctive quetia-
pine thus needs further study.
Other antipsychotic agents
The use of amisulpride as an adjunctive drug to SRI was 
shown to be effective in open-label study, but not in a 
RCT.59) Other open-label studies conducted to identify the 
effects of clozapine60) and aripiprazole61) as adjunctive 
drugs to SRIs showed negative results. In a study that 
compared the effects of ziprasidone and quetiapine as ad-
juncts in the treatment of refractory OCD, ziprasidone was 
found to be less effective than quetiapine.62)
THE NEED FOR LONG-TERM TREATMENT
OCD is a chronic disease that can recur in 90% of pa-
tients after remission if medication is suddenly stopped.63) 
Given this high recurrence rate, long-term treatment to 
maintain remission is critical. However, unlike the case 
with depression, studies on long-term treatment to main-
tain remission in OCD patients are rare. Recent studies 
showed that lower doses than initial-response doses can 
successfully control the symptoms of OCD.64) As with 
drug treatment for general mental disorders, for OCD pa-
tients, a high dose is required during the acute phases, and 
a minimal dose should be maintained for the remission pe-
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Table 3. Other antidepressant in treatment of OCD patient
Type of drugs Author Year Design Dose (mg) Result
SNRI Venlafaxine Albert et al.75) 2002 Single blind 225-350 Positive
Denys et al.17) 2003 Double blind 300 Positive
Milnacipran Sugimoto et al.76) 2007 Animal study 10 mg/Kg Positive
Duloxetine Dellosso et al.77) 2008 Case Study 120 Positive
NaSSA Miltazapine Koran et al.78) 2005 Open Study 30-60 Positive
Pallanti et al.21) 2004 Single blind 15-30 (Aug) Negative
NDRI Bupropion Denys et al.79) 2005 Open study 300 Negative
SNRI, serotonin norepineprine reuptake inhibitor; NaSSA, noradrenergic and specific serotonergic antidepressants; NDRI, norepineprine 
dopamine reuptake inhibitor.
riod when the symptoms have been alleviated.
RECENT ISSUES
Psychiatric Neurology: DBS and TMS
Psychiatric neurology, particularly stereotactic abla-
tion, was initiated in the 1940s and has been used in sev-
eral centers in Europe and the U.S. This approach has been 
seen of late in the form of an irreversible neurosurgical 
procedure (cingulotomy and capsulotomy) and as a rever-
sible neurosurgical procedure (i.e., deep brain stimulation 
or DBS) for the treatment of mental disorders as the public 
awareness of such methods has been revived,65) and as its 
effectiveness has been shown.66,67) In particular, DBS was 
approved by the FDA for the treatment of patients with ob-
stinate OCD, and discussions are underway for the prepa-
ration of ethical guidelines and criteria for patients with 
indications for the medication before its clinical use.68-71) 
Another new neuromodulatory procedure is transcranial 
magnetic stimulation (TMS), a noninvasive, reversible 
method involving the stimulation of the cerebral cortex. In 
earlier studies, TMS was effective in improving the symp-
toms of OCD patients, but a recent meta-analysis did not 
show its effectiveness.72) Several unsolved problems re-
main in the neurosurgical treatment of OCD. Although 
neurosurgical procedures are effective treatment methods 
for OCD, it is recommended that the optimal surgical site 
be chosen, that the target area be minimized, and that re-
petitive and high-radiation doses be avoided because of 
the risk of adverse reactions.67)
Venlafaxine
Several antidepressants have been introduced, but their 
effectiveness in the treatment of OCD has not been 
established. The effectiveness of venlafaxine, a new sero-
tonin-norepinephrine reuptake inhibitor (SNRI) anti-
depressant, was positive in some case reports and open-la-
bel studies.73,74) A single double-blind study showed no 
significant difference in effectiveness between venlafax-
ine and CMI.75) Another double-blind study revealed no 
difference in effectiveness between venlafaxine and 
paroxetine.19) However, another study showed that ven-
lafaxine exacerbated compulsive symptoms in one-third 
of the patients. Venlafaxine is recommended as the sec-
ond-line treatment drug for OCD patients requiring high 
doses (Table 3).16)
CONCLUSION
Now that an appropriate OCD algorithm has been de-
veloped, we can determine primary medications and the 
corresponding treatment strategies for OCD. With these 
for a basis, we must determine more effective medical 
treatment strategies through clinical research. These stud-
ies will be invaluable in developing new treatment 
strategies. Currently, SSRIs are the first line of treatment 
for OCD; however, if SSRIs are ineffective, we are now 
able to add other potentially helpful drugs. As neuro-
surgical treatments are developed, possibilities of in-
vasive cures grow. Establishing and maintaining a clinical 
database of potential and effective OCD treatments is 
crucial.
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